Stockreport

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Palisade Bio, Inc.  (PALI) 
PDF Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on [Read more]